UNSPSC 51151521: Benzpyrinium

This classification denotes a cholinergic agonist with the molecular formula C15H17N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P00DM5T7ZS, chemically known as 1-benzyl-3-hydroxypyridinium dimethylcarbamate but generally known as benzpyrinium, which bears US NIH Compound Identifier 11481. European Medicines Agency schedules Benzpyrinium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05766MIG. The term BENZPYRINIUM is an International Non-Proprietary Name.

As of Q4 2014, BENZPYRINIUM remains the US FDA Preferred Term for this commodity. Benzpyrinium bears US NLM identifiers UMLS ID C0599261 and NCI Concept Code C87446. SMILES: CN(C)C(=O)OC1=C[N+](=CC=C1)CC2=CC=CC=C2.

UNSPSC 51151521 Benzpyrinium is a Commodity code that in recent state and local procurement activity covers naloxone and drug deactivation systems procured by public health authorities. The solicitations under this code show state and local governments purchasing pharmaceutical harm-reduction products—specifically opioid overdose reversal agents and controlled-substance disposal systems—for community health and emergency response. Issuing bodies include county health departments and state health and human services commissions. Seminole County, Florida has solicited naloxone and safe drug deactivation systems through competitive bid, while the Texas Health and Human Services Commission has issued a Request for Information exploring direct-to-manufacturer prescription fulfillment models that would expand access to pharmaceutical products across state employee and retiree health plans.

Recent activity is concentrated in Florida and Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, and quarterly delivery to the Seminole County Community Health Building in Sanford; the contract carries a two-year initial term with one-year renewal option and requires E-Verify compliance, drug-free workplace certification, and standard insurance coverage. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would establish direct contracting relationships between state health plans and pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. Neither procurement specifies set-aside designations for disadvantaged enterprises.